Training | 2011.04.02
Allostem Therapeutics Teams with Crown Biosciences for Phase0 Oncology...
Crown Bioscience, Inc. announces their partnership with Allostem Therapeutics providing discovery and pre-clinical translational oncology services for Allostem’s MEK inhibitor program. CIP-137401 is...
(PRWeb April 01, 2011)
Read the full story at http://www.prweb.com/releases/2011/04/prweb5212244.htm
For more information, please visit
http://www.prweb.com/releases/2011/04/prweb5212244.htm
